Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 3273K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bull, M. J. Articles by Wang, E. C. Y. Search for Related Content PubMed PubMed Citation Articles by Bull, M. J. Articles by Wang, E. C. Y. Related Collections Related In this Issue article Social Bookmarking                            What's this?

¹ Department of Medical Biochemistry and Immunology, ² Department of Rheumatology, and ³ Department of Child Health, School of Medicine, Heath Park, Cardiff CF14 4XN, Wales, UK
⁴ Cancer Sciences Division, University of Southampton School of Medicine, Southampton SO16 6YD, England, UK

CORRESPONDENCE Eddie Chung Yern Wang: WangEC{at}cf.ac.uk

Rheumatoid arthritis (RA) is a chronic inflammatory disease of synovial joints that is associated with cartilage and bone destruction. Death Receptor 3 (DR3), a tumor necrosis factor (TNF) receptor superfamily member, has recently been associated with the pathogenesis of RA. We demonstrate that absence of DR3 confers resistance to the development of adverse bone pathology in experimental antigen-induced arthritis (AIA). DR3^ko mice exhibited a reduction in all histopathological hallmarks of AIA but, in particular, failed to develop subchondral bone erosions and were completely protected from this characteristic of AIA. In contrast, TNF-like protein 1A (TL1A), the ligand for DR3, exacerbated disease in a dose- and DR3-dependent fashion. Analysis of osteoclast number within AIA joint revealed a reduction in areas susceptible to bone erosion in DR3^ko mice, whereas in vitro osteoclastogenesis assays showed that TL1A could directly promote osteoclastogenesis in mouse and man. Treatment with antagonistic anti-TL1A mAb protected animals in a systemic model of RA disease collagen-induced arthritis. We therefore conclude that the DR3–TL1A pathway regulates joint destruction in two murine models of arthritis and represents a potential novel target for therapeutic intervention in inflammatory joint disease.

© 2008 Bull et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related In this Issue article

Death receptor chews up bone

Amy Maxmen
J. Exp. Med. 2008 205: 2452. [Full Text] [PDF]

This article has been cited by other articles:

• Zhang, J., Wang, X., Fahmi, H., Wojcik, S., Fikes, J., Yu, Y., Wu, J., Luo, H. (2009). Role of TL1A in the Pathogenesis of Rheumatoid Arthritis. J. Immunol. 183: 5350-5357 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS